# US 2017/0258890 A1 · Genetically stable replication competent sendai virus vector(s) containing and expressing optimized hiv genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0258890 A1
- Document ID: US20170258890A1
- Status: Published application
- Kind: A1
- Application number: 15/498,554
- Filed: 2017-04-27
- Published: 2017-09-14
- Earliest claimed: 2014-10-27
- Inventors: John Coleman; Josephine Helena Cox; Arban Domi; Hiroto Hara; Takashi Hironaka; Makoto Inoue; Dagna Skoog Laufer; Angela Grazia Lombardo; Christopher L. Parks; Eddy Sayeed; Maoli Yuan; Xinsheng Zhang
- Web page: https://patentgrep.com/patent/US20170258890A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/12: Viral antigens
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61P 31/18: for HIV
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16271: Demonstrated in vivo effect
- C12N 2740/16334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18443: viral genome or elements thereof as genetic vector
- C12N 2760/18843: viral genome or elements thereof as genetic vector
- C12N 2760/18871: Demonstrated in vivo effect
- C12N 2760/20243: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes, methods for making the same and cell substrates qualified for vaccine production which may comprise genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes.

## Claims

### Claim 1

A genetically stable Sendai virus (SeV) vector containing and expressing a nucleic acid encoding an optimized human immunodeficiency virus (HIV) immunogen, wherein the HIV immunogen is a Clade A Env-G hybrid or a Clade A Env-F hybrid based on BG505, a HIVCON coding sequence modified for use in negative-strand RNA virus vectors, a HIVCON with C5 env-tag optimized for a pDNA vector.

### Claim 2 (depends on 1)

The vector of claim 1, wherein the nucleic acid comprises the nucleic acid sequence of FIG. 2, 4, 6A or 25.

### Claim 3 (depends on 1)

The vector of claim 1, wherein the amino acid sequence of the HIV immunogen comprises the amino acid sequence of FIG. 1, 5 or 6C.

### Claim 4

A vector comprising the sequence of any one of the nucleic acid sequences of FIG. 8.

### Claim 5

A vector containing and expressing a nucleic acid sequence of any one of the nucleic acid sequences of FIG. 23, FIG. 24, FIG. 25 or FIG. 26.

### Claim 6 (depends on 5)

The vector of claim 5, wherein the vector is a SeV vector.

### Claim 7 (depends on 1)

A cell transfected with the vector of claim 1.

### Claim 8 (depends on 7)

The cell of claim 7, wherein the cell is a Vero cell.

### Claim 9 (depends on 1)

A method for eliciting an immune response against HIV comprising administering an effective amount of the vector of claim 1 to a mammal in need thereof.

### Claim 10 (depends on 9)

The method of claim 9 further comprising administering an adjuvant.

### Claim 11 (depends on 10)

The method of claim 10, wherein the adjuvant is comprised of an acrylic polymer.
